Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists ,
Cutaneous side effects of anti???tumor necrosis factor biologic therapy: A clinical review, Journal of the American Academy of Dermatology, vol.61, issue.3, pp.486-504, 2009. ,
DOI : 10.1016/j.jaad.2008.10.060
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study, Arthritis Research & Therapy, vol.7, issue.3, pp.666-676, 2005. ,
DOI : 10.1186/ar1724
??v??nements cutan??omuqueux au cours des traitements par anti-TNF alpha??: ??tude observationnelle prospective de 41??cas, Annales de Dermatologie et de V??n??r??ologie, vol.137, issue.1, pp.12-20, 2010. ,
DOI : 10.1016/j.annder.2009.12.003
Manifestations cutan??es observ??es au cours d???un traitement par anti-TNF alpha : 11 observations, Annales de Dermatologie et de V??n??r??ologie, vol.134, issue.4, pp.337-379, 2007. ,
DOI : 10.1016/S0151-9638(07)89187-3
Manifestations cutanées paradoxales des anti-TNF-alpha. Annales de Dermatologie et de Vénéréologie, pp.64-71, 2010. ,
DOI : 10.1016/j.annder.2009.10.004
Risk of nonmelanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011 août, pp.1431-1440 ,
Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors, J. Rheumatol, vol.32, issue.11, pp.2130-2135, 2005. ,
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action, Arthritis & Rheumatism, vol.44, issue.7 ,
DOI : 10.1002/art.23835
Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases, Journal of Dermatological Treatment, vol.174, issue.15, pp.100-108, 2009. ,
DOI : 10.1016/S0140-6736(02)08512-4
Tumor Necrosis Factor-?? Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata, American Journal of Clinical Dermatology, vol.56, issue.1, pp.1-14, 2008. ,
DOI : 10.2165/00128071-200809010-00001
Dermatological complications and safety of anti-TNF treatments, Gut, vol.58, issue.8 ,
DOI : 10.1136/gut.2008.163683
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis, Seminars in Arthritis and Rheumatism, vol.39, issue.5 ,
DOI : 10.1016/j.semarthrit.2008.10.002
Predictors of infection in rheumatoid arthritis Arthritis Rheum Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate, Ann. Rheum. Dis, vol.4653, issue.94, pp.2294-300, 1994. ,
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, JAMA. févr, vol.18301, issue.7, pp.737-781, 2009. ,
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Annals of the Rheumatic Diseases, vol.68, issue.1 ,
DOI : 10.1136/ard.2007.083188
Safety profile of abatacept in rheumatoid arthritis: A review, Clinical Therapeutics, vol.32, issue.11, pp.1855-70, 2010. ,
DOI : 10.1016/j.clinthera.2010.10.011
Abatacept treatment for rheumatoid arthritis Rheumatology (Oxford) 2011 mars, pp.437-486 ,
Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy, Drug Des Devel Ther, vol.5, pp.61-70, 2011. ,
B cell non-Hodgkin's lymphoma: rituximab safety experience, Arthritis Res ,
Lesiones cut??neas en una paciente con linfoma no Hodgkin, Enfermedades Infecciosas y Microbiolog??a Cl??nica, vol.25, issue.7, pp.489-90, 2007. ,
DOI : 10.1157/13108713
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B, Acta Biomed, vol.77, issue.2, pp.32-37, 2006. ,
Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study, Arthritis & Rheumatism, vol.92, issue.9, pp.2886-95, 2007. ,
DOI : 10.1002/art.22864
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006. ,
DOI : 10.1001/jama.295.19.2275
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Annals of the Rheumatic Diseases, pp.1421-1427, 2005. ,
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, Arthritis & Rheumatism, vol.21, issue.2, pp.762-84, 2008. ,
DOI : 10.1002/art.23721
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies, Rheumatology, vol.49, issue.11, pp.2217-2226, 2010. ,
DOI : 10.1093/rheumatology/keq249a
Risk of skin cancer in the drug treatment of rheumatoid arthritis, Expert Opinion on Drug Safety, vol.32, issue.5 ,
DOI : 10.1002/ajh.21003
Evaluation of information about prophylactic treatment and management of hand-foot reactions caused by antiangiogenic therapies], Ann Dermatol Venereol, vol.138, pp.8-9565, 2011. ,
Skin immune sentinels in health and disease, Nature Reviews Immunology, vol.182 ,
DOI : 10.1038/nri2622
Annales de Dermatologie et de Vénéréologie, pp.257-262, 2009. ,
The skin barrier as an innate immune element, Seminars in Immunopathology, vol.11, issue.Pt 3, pp.3-14, 2007. ,
DOI : 10.1007/s00281-007-0060-9
Innate immunity, Current Opinion in Immunology, vol.15, issue.1, pp.338-382, 2000. ,
DOI : 10.1016/S0952-7915(02)00019-5
URL : https://hal.archives-ouvertes.fr/hal-01438527
Regulation of Adaptive Immunity by the Innate Immune System, Science, vol.327, issue.5963 ,
DOI : 10.1126/science.1183021
The immune system. First of two parts, N. Engl. J. Med. 2000 juill, vol.6343, issue.1, pp.37-49 ,
An overview of the immune system, The Lancet, vol.357, issue.9270, pp.1777-89, 2001. ,
DOI : 10.1016/S0140-6736(00)04904-7
Toll-Like Receptors in Skin, Advances in Dermatology, vol.24, pp.71-87, 2008. ,
DOI : 10.1016/j.yadr.2008.09.004
Toll-like receptors in innate immunity. International Immunology, 2005. ,
Immune response modifiers ? mode of action, Experimental Dermatology, vol.21, issue.5, pp.331-372, 2006. ,
DOI : 10.1023/B:APPT.0000025805.55340.c3
Toll-like receptors in the skin Delves PJ, Roitt IM. The immune system. Second of two parts, Semin Immunopathol. N. Engl. J. Med, vol.29343, issue.12, pp.15-26, 2000. ,
Cancer immunoediting: from immunosurveillance to tumor escape, Nature Immunology, vol.3, issue.11, pp.991-999, 2002. ,
DOI : 10.1038/ni1102-991
Harnessing the immune system to treat cancer, Journal of Clinical Investigation, vol.117, issue.5, pp.1130-1136, 2007. ,
DOI : 10.1172/JCI32136
Natural Innate and Adaptive Immunity to Cancer, Annual Review of Immunology, vol.29, issue.1, pp.235-71, 2011. ,
DOI : 10.1146/annurev-immunol-031210-101324
Cutaneous dendritic cells, Seminars in Immunology, vol.17, issue.4, pp.273-83, 2005. ,
DOI : 10.1016/j.smim.2005.05.009
Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells, Nature Reviews Immunology, vol.103, issue.12, pp.935-982, 2008. ,
DOI : 10.1038/nri2455
Plasmacytoid Dendritic Cells: Recent Progress and Open Questions, Annual Review of Immunology, vol.29, issue.1, pp.163-83, 2011. ,
DOI : 10.1146/annurev-immunol-031210-101345
Langerhans cell migration. An essential step in the induction of contact hypersensitivity], Ann Dermatol Venereol, vol.129, pp.8-91071, 2002. ,
Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity, J. Immunol, vol.155, issue.9, pp.4207-4224, 1995. ,
Insights into Langerhans cell function from Langerhans cell ablation models, European Journal of Immunology, vol.204, issue.9, pp.2369-76, 2008. ,
DOI : 10.1002/eji.200838397
The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases, Annual Review of Immunology, vol.29, issue.1, pp.707-742, 2011. ,
DOI : 10.1146/annurev-immunol-031210-101405
Innate antimicrobial peptides in the skin, Med Sci, vol.22, issue.2, pp.153-160, 2006. ,
Tumour necrosis factor-??-induced migration of human Langerhans cells: the influence of ageing, British Journal of Dermatology, vol.94, issue.Suppl. 35, pp.32-40, 2002. ,
DOI : 10.1046/j.1365-2133.2002.04549.x
Human keratinocyte induction of rapid effector function in antigen-specific memory CD4+ and CD8+ T cells, European Journal of Immunology, vol.274, issue.6 ,
DOI : 10.1002/eji.200636915
Innate IL-17-producing cells: the sentinels of the immune system, Nature Reviews Immunology, vol.31, issue.7, pp.479-89, 2010. ,
DOI : 10.1038/nri2800
Th17 cells: A new paradigm for cutaneous inflammation, Journal of Dermatological Treatment, vol.174, issue.5, pp.259-66, 2008. ,
DOI : 10.1080/09546630802206686
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2), The Lancet, vol.371, issue.9625, 2008. ,
DOI : 10.1016/S0140-6736(08)60726-6
Dendritic Cells and T Cells in the Regulation of Cutaneous Immunity, Advances in Dermatology, vol.23, pp.307-340, 2007. ,
DOI : 10.1016/j.yadr.2007.07.014
FOXP3+ regulatory T cells in the human immune system, Nature Reviews Immunology, vol.34, issue.7, pp.490-500, 2010. ,
DOI : 10.1038/nri2785
Regulatory T cells ??? a brief history and perspective, European Journal of Immunology, vol.25, issue.S1, pp.3-17, 2011. ,
DOI : 10.1002/eji.200737593
Innate immune functions of human ???? T cells, Immunobiology, vol.213, issue.3-4, pp.3-4173, 2008. ,
DOI : 10.1016/j.imbio.2007.10.006
???? T cell effector functions: a blend of innate programming and acquired plasticity, Nature Reviews Immunology, vol.18, issue.7, pp.467-78, 2010. ,
DOI : 10.1038/nri2781
Mast cell functions in the innate skin immune system, Immunobiology, vol.213, issue.3-4 ,
DOI : 10.1016/j.imbio.2007.10.017
Mast-cell responses to pathogens, Nature Reviews Immunology, vol.63, issue.10, pp.787-99, 2004. ,
DOI : 10.1084/jem.192.12.1849
Photoimmunosuppression, Photodermatology, Photoimmunology & Photomedicine, vol.276, issue.3, pp.141-146, 2002. ,
DOI : 10.1034/j.1600-0781.2002.180307.x
Mechanisms involved in ultraviolet light-induced immunosuppression, Eur J Dermatol, vol.13, issue.6, pp.515-538, 2003. ,
Alterations in human epidermal Langerhans cells by ultraviolet radiation: quantitative and morphological study, British Journal of Dermatology, vol.3, issue.2, pp.291-300, 2003. ,
DOI : 10.1046/j.1365-2133.1996.d01-732.x
Chronological ageing and photoageing of dendritic cells, Clinical and Experimental Dermatology, vol.106, issue.7, pp.608-620, 2001. ,
DOI : 10.1016/S0923-1811(99)00076-6
Regulation of cutaneous immunity by the environment: An important role for UV irradiation and vitamin D, International Immunopharmacology, vol.9, issue.5, pp.587-596, 2009. ,
DOI : 10.1016/j.intimp.2009.01.024
The role of cytokines in UV-induced systemic immune suppression, Journal of Dermatological Science, vol.23 ,
DOI : 10.1016/S0923-1811(99)00073-0
Regulation of ultraviolet radiation induced cutaneous photoimmunosuppression by Toll-like receptor-4, Archives of Biochemistry and Biophysics, vol.508, issue.2, pp.171-178, 2011. ,
DOI : 10.1016/j.abb.2011.01.005
Thérapeutique Dermatologique Médecine Science Flammarion. 48 UV-B radiation induces the expression of antimicrobial peptides in human keratinocytes in vitro and in vivo, J ,
Non-melanoma skin cancers and human papillomavirus], Ann Dermatol Venereol, vol.13012, issue.1, pp.1131-1139, 2003. ,
Human papillomavirus infection of non-melanoma skin cancers in immunocompetent hosts. Cancer Letters, pp.83-91, 2000. ,
Differential p53-mediated responses to solar-simulated radiation in human papillomavirus type 16-infected keratinocytes, Experimental Dermatology, vol.21, issue.6, pp.476-84, 2007. ,
DOI : 10.1093/emboj/18.5.1223
Ubiquitination in host immune response to human papillomavirus infection, Archives of Dermatological Research, vol.47, issue.7, pp.217-247, 2011. ,
DOI : 10.1007/s00403-011-1141-0
Potential strategies utilised by papillomavirus to evade host immunity 54. O'Brien PM, Saveria Campo M. Evasion of host immunity directed by papillomavirusencoded proteins, Immunol. Rev. Virus Res, vol.16888, issue.12, pp.131-42103, 1999. ,
Innate immunity and aging, Experimental Gerontology, vol.43, issue.8, pp.718-746, 2008. ,
DOI : 10.1016/j.exger.2008.05.016
Aging and the Skin Immune System, Archives of Dermatology, vol.133, issue.10, pp.1256-62, 1997. ,
DOI : 10.1001/archderm.1997.03890460078009
Skin ageing and immune competence, British Journal of Dermatology, vol.92, issue.s35, 1990. ,
DOI : 10.1007/BF00412884
Ageing and photoageing of keratinocytes and melanocytes, Clinical and Experimental Dermatology, vol.10, issue.7 ,
DOI : 10.1073/pnas.180320897
Topical Immunomodulation in Dermatology, Dermatologic Surgery, vol.30, issue.8, pp.1101-1113, 2004. ,
DOI : 10.1097/00042728-200408000-00008
Mechanism of Action and Emerging Role of Immune Response Modifier Therapy in Dermatologic Conditions, Journal of Cutaneous Medicine & Surgery, vol.134, issue.suppl, pp.3-12, 2004. ,
DOI : 10.1007/s10227-004-0803-3
Toll-like receptor 7 agonists and skin. Drug News Perspect, pp.158-65, 2008. ,
Imiquimod: modes of actionTNF alpha in the physiopathology of psoriasis], Br. J. Dermatol. Ann Dermatol Venereol, vol.149133, issue.2, pp.174-80, 2003. ,
Tumour necrosis factor ??: a potential target for the therapy of solid tumours, The Lancet Oncology, vol.4, issue.9, pp.565-73, 2003. ,
DOI : 10.1016/S1470-2045(03)01196-3
Tumour necrosis factor and cancer, Nature Reviews Cancer, vol.265, issue.5, pp.361-71, 2009. ,
DOI : 10.1038/nature01322
Comparative Overview of Safety of the Biologics in Rheumatoid Arthritis. The Journal of Rheumatology Supplement, pp.25-32, 2009. ,
British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti?tumor necrosis factor therapy ,
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management, The Lancet Infectious Diseases, vol.3, issue.3, pp.148-55, 2003. ,
DOI : 10.1016/S1473-3099(03)00545-0
TNF: a tumor-suppressing factor or a tumor-promoting factor? Future Oncol, pp.1833-1839, 2010. ,
The use of biological agents in the treatment of rheumatoid arthritis ,
TNF?? blockade in human diseases: Mechanisms and future directions, Clinical Immunology, vol.126, issue.2, pp.121-157, 2008. ,
DOI : 10.1016/j.clim.2007.08.013
Roles of B cells in rheumatoid arthritis, Arthritis Research & Therapy, vol.5, issue.Suppl 4, pp.1-6, 2003. ,
DOI : 10.1186/ar1010
Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis RéfleXions Rhumatologiques: Blocage de l'IL-6, CMAMD. 2010 déc, vol.193, pp.81-90, 2009. ,
Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy, Drug Des Devel Ther, vol.5, pp.61-70 ,
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor ?? Inhibition, New England Journal of Medicine, vol.353, issue.11, pp.1114-1137, 2005. ,
DOI : 10.1056/NEJMoa050524
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, Arthritis & Rheumatism, vol.21, issue.2, pp.762-84, 2008. ,
DOI : 10.1002/art.23721
Recommendations of the French Society for Rheumatology regarding TNF?? antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update, Joint Bone Spine, vol.74, issue.6, pp.638-684, 2007. ,
DOI : 10.1016/j.jbspin.2007.10.003
Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis. Best Practice & Research Clinical Rheumatology, pp.589-604, 2010. ,
TNF? blockade in human diseases: An overview of efficacy and safety. Clinical Immunology 88. CRI. Fiches pratiques. Utilisation du Tocilizumab dans les spondylarthrites Classification criteria for psoriatic arthritis: Development of new criteria from a large international study, Revue du Rhumatisme Arthritis Rheum, vol.12654, issue.768, pp.13-302665, 2006. ,
Guideline for anti-TNF-?? therapy in psoriatic arthritis, Rheumatology, vol.44, issue.3, pp.390-397, 2005. ,
DOI : 10.1093/rheumatology/keh514
Management of psoriatic arthritis, Indian Journal of Dermatology, Venereology, and Leprology, vol.76, issue.6, pp.645-51, 2010. ,
DOI : 10.4103/0378-6323.72457
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial CRI. Fiches pratiques. Utilisation des anti-TNF?: autres indications, Lancet. Revue du rhumatisme, vol.37277, issue.9636, pp.383-91, 2007. ,
Predictors of infection in rheumatoid arthritis, Arthritis & Rheumatism, vol.140, issue.9, pp.2294-300, 2002. ,
DOI : 10.1002/art.10529
Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis, Annals of the Rheumatic Diseases, vol.66, issue.3 ,
DOI : 10.1136/ard.2006.057265
Traitements immunosuppresseurs chez les patients à risque. 2007. 100 Nonmelanoma skin cancers and glucocorticoid therapy, Br. J. Cancer, vol.85, issue.5, pp.683-689, 2001. ,
Skin Cancers and Non-Hodgkin Lymphoma Among Users of Systemic Glucocorticoids: A Population-Based Cohort Study, JNCI Journal of the National Cancer Institute, vol.96, issue.9, pp.709-720, 2004. ,
DOI : 10.1093/jnci/djh118
Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case???control study, British Journal of Cancer, vol.58, issue.1, pp.200-205, 2009. ,
DOI : 10.1136/bmj.39507.551644.BE
Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis, The Journal of Rheumatology, vol.37, issue.11, pp.2205-2220, 2010. ,
DOI : 10.3899/jrheum.100041
Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors, J. Rheumatol, vol.32, issue.11, pp.2130-2135, 2005. ,
Leflunomide, Indian Journal of Dermatology, Venereology and Leprology, vol.75, issue.4, pp.422-426, 2009. ,
DOI : 10.4103/0378-6323.53157
Multiple forms of DNA Damage Caused by UVA Photoactivation of DNA 6-Thioguanine, Photochemistry and Photobiology, vol.30, issue.1, pp.5-13, 2012. ,
DOI : 10.1111/j.1751-1097.2011.01043.x
Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study, Journal of Gastroenterology and Hepatology, vol.22, issue.80, pp.385-394, 2012. ,
DOI : 10.1111/j.1440-1746.2011.06865.x
Cutaneous side effects of anti???tumor necrosis factor biologic therapy: A clinical review, Journal of the American Academy of Dermatology, vol.61, issue.3, pp.486-504, 2009. ,
DOI : 10.1016/j.jaad.2008.10.060
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study, Arthritis Research & Therapy, vol.7, issue.3, pp.666-676, 2005. ,
DOI : 10.1186/ar1724
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists ,
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Annals of the Rheumatic Diseases, pp.1421-1427, 2005. ,
The risk of malignancy associated with psoriasis, Arch Dermatol, vol.137, issue.6, pp.778-83, 2001. ,
Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study, The Lancet, vol.358, issue.9287, pp.1042-1047, 2001. ,
DOI : 10.1016/S0140-6736(01)06179-7
Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies, Clinics in Dermatology, vol.28, issue.1, pp.88-92, 2010. ,
DOI : 10.1016/j.clindermatol.2009.03.003
Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study, Journal of Investigative Dermatology, vol.120, issue.2, pp.211-217, 2003. ,
DOI : 10.1046/j.1523-1747.2003.12040.x
Treatments for psoriasis and the risk of malignancy, Journal of the American Academy of Dermatology, vol.60, issue.6, pp.1001-1018, 2009. ,
DOI : 10.1016/j.jaad.2008.12.031
PUVAth??rapie et cancers cutan??s, Annales de Dermatologie et de V??n??r??ologie, vol.131, issue.5, pp.437-480, 2004. ,
DOI : 10.1016/S0151-9638(04)93636-8
Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV- A radiation (PUVA) A meta-analysis, Arch Dermatol, vol.134, issue.12, pp.1582-1587, 1998. ,
The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor ? receptor IgG1-Fc fusion complex therapy, Exp. Cell Res. Journal of the American Academy of Dermatology, vol.31345, issue.1216, pp.2345-55953, 2001. ,
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, Arthritis & Rheumatism, vol.21, issue.2, pp.762-84, 2008. ,
DOI : 10.1002/art.23721
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies, Rheumatology, vol.49, issue.11, pp.2217-2226, 2010. ,
DOI : 10.1093/rheumatology/keq249a
Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study, Arthritis & Rheumatism, vol.92, issue.9, pp.2886-95, 2007. ,
DOI : 10.1002/art.22864
Risk of skin cancer in the drug treatment of rheumatoid arthritis, Expert Opinion on Drug Safety, vol.32, issue.5 ,
DOI : 10.1002/ajh.21003
Dermatological complications and safety of anti-TNF treatments, Gut, vol.58, issue.8 ,
DOI : 10.1136/gut.2008.163683
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006. ,
DOI : 10.1001/jama.295.19.2275
Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab, Journal of the American Academy of Dermatology, vol.50, issue.5, 2004. ,
DOI : 10.1016/j.jaad.2003.11.044
Non-melanoma and melanoma skin cancer risk in a national cohort of veterans with RA, 2009. ,
Tumor necrosis factor ?? antagonist use and cancer in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.14, issue.9, pp.2757-64, 2006. ,
DOI : 10.1002/art.22056
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register, Arthritis Care & Research, vol.56, issue.Suppl 2, pp.755-63, 2010. ,
DOI : 10.1002/acr.20129
No Evidence for Increased Risk of Cutaneous Squamous Cell Carcinoma in Patients With Rheumatoid Arthritis Receiving Etanercept for Up to 5 Years, Archives of Dermatology, vol.141, issue.7, pp.861-865, 2005. ,
DOI : 10.1001/archderm.141.7.861
Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials, Annals of the Rheumatic Diseases, vol.68, issue.7, pp.1177-83, 2009. ,
DOI : 10.1136/ard.2008.094904
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events, Annals of the Rheumatic Diseases, vol.68, issue.7, pp.1136-1181, 2009. ,
DOI : 10.1136/ard.2008.091025
Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum, pp.801-813, 2009. ,
Temporal Relationship Between Antitumor Necrosis Factor-?? Antibody Therapy and Recrudescence of Head and Neck Squamous Cell Carcinoma, The Laryngoscope, vol.13, issue.3, pp.450-452, 2008. ,
DOI : 10.1097/MLG.0b013e31815abf4c
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum, pp.3180-3189, 2009. ,
Mortality in rheumatoid arthritis, update, 2008. ,
Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate, J. Rheumatol. Ann. Rheum. Dis, vol.3753, issue.54, pp.928-31224, 1994. ,
Does Anti-Tumor Necrosis Factor-{alpha} Therapy Affect Risk of Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Longterm Data, J Rheumatol ,
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis, Seminars in Arthritis and Rheumatism, vol.39, issue.5 ,
DOI : 10.1016/j.semarthrit.2008.10.002
Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis & Rheumatism, vol.47, issue.11, pp.3403-3415, 2005. ,
DOI : 10.1002/art.21386
Mycobacterium abscessus infection after use of tumor necrosis factor ?? inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor ?? inhibitor use, Diagnostic Microbiology and Infectious Disease, vol.53, issue.3, pp.233-241, 2005. ,
DOI : 10.1016/j.diagmicrobio.2005.06.006
Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis, International Journal of Rheumatic Diseases, vol.9, issue.Suppl. 2, pp.12-26, 2010. ,
DOI : 10.1111/j.1756-185X.2009.01457.x
Infections during tumour necrosis factor-?? blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients, Rheumatology, vol.46, issue.2, pp.327-361, 2007. ,
DOI : 10.1093/rheumatology/kel236
Tumor necrosis factor blockade and the risk of viral infection, Nature Reviews Rheumatology, vol.43, issue.3, pp.165-74, 2010. ,
DOI : 10.1038/nrrheum.2009.279
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, JAMA. févr, vol.18301, issue.7, pp.737-781, 2009. ,
Development of primary varicella infection during infliximab treatment for psoriasis, Journal of the American Academy of Dermatology, vol.60, issue.4, 2009. ,
DOI : 10.1016/j.jaad.2008.10.002
Infection cutanée à Mycobacterium chelonae au cours d'un traitement par anti-TNF. Annales de Dermatologie et de Vénéréologie, pp.811-815, 2009. ,
DOI : 10.1016/j.annder.2009.09.008
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly, Rheumatology, vol.50, issue.1, pp.124-155, 2011. ,
DOI : 10.1093/rheumatology/keq242
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists ,
Serious infection following anti???tumor necrosis factor ?? therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies, Arthritis & Rheumatism, vol.54, issue.9, pp.2896-904, 2007. ,
DOI : 10.1002/art.22808
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety, BMC Musculoskeletal Disorders, vol.36, issue.42, p.52, 2008. ,
DOI : 10.1080/03009740701607067
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists, Annals of the Rheumatic Diseases, vol.66, issue.10, pp.1339-1383, 2007. ,
DOI : 10.1136/ard.2006.062760
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial, Arthritis & Rheumatism, vol.46, issue.4, pp.1075-86, 2006. ,
DOI : 10.1002/art.21734
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action, Arthritis & Rheumatism, vol.44, issue.7 ,
DOI : 10.1002/art.23835
Tumor Necrosis Factor-?? Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata, American Journal of Clinical Dermatology, vol.56, issue.1, pp.1-14, 2008. ,
DOI : 10.2165/00128071-200809010-00001
Manifestations cutanées paradoxales des anti-TNF-alpha. Annales de Dermatologie et de Vénéréologie, pp.64-71, 2010. ,
DOI : 10.1016/j.annder.2009.10.004
Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases, Journal of Dermatological Treatment, vol.174, issue.15, pp.100-108, 2009. ,
DOI : 10.1016/S0140-6736(02)08512-4
Onset or exacerbation of cutaneous psoriasis during TNF?? antagonist therapy, Joint Bone Spine, vol.75, issue.3, pp.315-323, 2008. ,
DOI : 10.1016/j.jbspin.2007.06.011
Rates of newonset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for, Rheumatology Biologics Register ,
Anti-tumor necrosis factor-alpha-induced psoriasis, J. Rheumatol, vol.33, issue.7, pp.1411-1415, 2006. ,
Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?, J. Rheumatol, vol.34, issue.2, pp.438-447, 2007. ,
Autoimmune diseases induced by TNF-targeted therapies, Best Practice & Research Clinical Rheumatology, vol.22, issue.5, pp.847-61, 2008. ,
DOI : 10.1016/j.berh.2008.09.008
Granuloma annulare induced by anti-tumour necrosis factor therapy, Annals of the Rheumatic Diseases, vol.67, issue.4, pp.567-70, 2008. ,
DOI : 10.1136/ard.2007.075663
URL : http://ard.bmj.com/cgi/content/short/67/4/567
Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody Therapy, Dermatology, vol.206, issue.4, pp.388-90, 2003. ,
DOI : 10.1159/000069965
Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors (Abstract) ,
Pelade au cours d'un traitement par anti-TNF alpha : neuf cas. Annales de Dermatologie et de Vénéréologie, pp.285-93, 2011. ,
Lichen planus associated with etanercept, British Journal of Dermatology, vol.34, issue.0 ,
DOI : 10.1111/j.1365-2133.2006.07478.x
174. CRI. Fiches pratiques. Utilisation de l'Abatacept. Revue du rhumatisme, pp.188-90, 2008. ,
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study, Arthritis & Rheumatism, vol.50, issue.9, pp.2807-2823, 2006. ,
DOI : 10.1002/art.22070
Safety profile of abatacept in rheumatoid arthritis: A review, Clinical Therapeutics, vol.32, issue.11, pp.1855-70, 2010. ,
DOI : 10.1016/j.clinthera.2010.10.011
Abatacept treatment for rheumatoid arthritis Rheumatology (Oxford) 2011 mars, pp.437-486 ,
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Annals of the Rheumatic Diseases, vol.68, issue.1 ,
DOI : 10.1136/ard.2007.083188
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis, The Korean Journal of Internal Medicine, vol.25, issue.1, pp.1-17, 2010. ,
DOI : 10.3904/kjim.2010.25.1.1
Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy, Drug Des Devel Ther, vol.5, pp.61-70, 2011. ,
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Annals of the Rheumatic Diseases, vol.69, issue.01, pp.88-96, 2010. ,
DOI : 10.1136/ard.2008.105197
183. Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience, Arthritis Res ,
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial, Arthritis & Rheumatism, vol.31, issue.5, pp.1390-400, 2006. ,
DOI : 10.1002/art.21778
Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab, Seminars in Arthritis and Rheumatism, vol.38, issue.4, pp.265-80, 2009. ,
DOI : 10.1016/j.semarthrit.2008.01.001
Lesiones cut??neas en una paciente con linfoma no Hodgkin, Enfermedades Infecciosas y Microbiolog??a Cl??nica, vol.25, issue.7, pp.489-90, 2007. ,
DOI : 10.1157/13108713
Fatal visceral varicellazoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma, Haematologica, vol.85, issue.8, pp.894-899, 2000. ,
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B, Acta Biomed, vol.77, issue.2, pp.32-37, 2006. ,
Rituximab-related viral infections in lymphoma patients, Leukemia & Lymphoma, vol.23, issue.1, pp.1307-1319, 2007. ,
DOI : 10.1182/blood-2002-10-3162
Involvement of interleukin-6 in the biology and metastatic activity of B16F10 melanoma cells (Abstract). Eur. Cytokine Netw, pp.187-92, 1998. ,
Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study, Cytokines, Cellular & Molecular Therapy, vol.7, issue.4, pp.151-157, 2002. ,
DOI : 10.1080/13684730210002328
Three Cases of Activation of Cutaneous Squamous-cell Carcinoma During Treatment with Prolonged Administration of Rituximab, Clinical Oncology, vol.18, issue.2, pp.155-161 ,
DOI : 10.1016/j.clon.2005.11.015
Rapid growth of Merkel cell carcinoma after treatment with rituximab, J Drugs Dermatol, vol.5, issue.2, pp.180-181, 2006. ,
Progression of classic Kaposi's sarcoma with rituximab, Journal of the American Academy of Dermatology, vol.53, issue.1 ,
DOI : 10.1016/j.jaad.2004.12.048
Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis (Abstract), Clin. Exp. Rheumatol, vol.25, issue.5, pp.46-56, 2007. ,
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial, Arthritis & Rheumatism, vol.20, issue.8, pp.2263-71, 2005. ,
DOI : 10.1002/art.21201
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study, Arthritis & Rheumatism, vol.50, issue.9, pp.2807-2823, 2006. ,
DOI : 10.1002/art.22070
Rituximab-induced vasculitis: A case report and review of the medical published work, The Journal of Dermatology, vol.94, issue.5, pp.284-291, 2009. ,
DOI : 10.1111/j.1346-8138.2009.00639.x
Stevens-Johnson syndrome after treatment with rituximab, Annals of Oncology, vol.13, issue.12, pp.1948-50, 2002. ,
DOI : 10.1093/annonc/mdf350